Engineered T-Cell Therapy

Engineered T cells are the result of turning a therapeutic process into a product capable of overcoming checkpoint inhibition, and are the future of adoptive immunotherapy. Cytokine release syndrome,” a storm of molecules generated as the cells fights the cancer. Instead of an antibody, single-chain target domain, he used a human cytokine, IL-13, with a mutation in the sequence that gave high affinity for IL-13 receptor α2. These cells were infused intra cranially, establishing the safety of intracranial administration with some antitumor responses.

    Related Conference of Engineered T-Cell Therapy

    April 04-05, 2024

    38th International Conference on Immunology

    Madrid, Spain
    May 23-24, 2024

    18th International Conference on European Immunology

    Zurich, Switzerland

    Engineered T-Cell Therapy Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in